Cargando…

The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

BACKGROUND: Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genomic clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mark, Kenneth M. K., Varn, Frederick S., Ung, Matthew H., Qian, Feng, Cheng, Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414335/ https://www.ncbi.nlm.nih.gov/pubmed/28464832 http://dx.doi.org/10.1186/s12885-017-3297-2

Ejemplares similares

Whole Transcriptome Signature for Prognostic Prediction (WTSPP): application of whole transcriptome signature for prognostic prediction in cancer
por: Schaafsma, Evelien, et al.
Publicado: (2020)

Regulators Associated with Clinical Outcomes Revealed by DNA Methylation Data in Breast Cancer
por: Ung, Matthew H., et al.
Publicado: (2015)

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

Integrative analysis of survival-associated gene sets in breast cancer
por: Varn, Frederick S, et al.
Publicado: (2015)

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures
por: Ji, Fei, et al.
Publicado: (2021)

Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
por: Li, Xinyan, et al.
Publicado: (2019)

Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis
por: Ung, Matthew H., et al.
Publicado: (2016)

Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles
por: Varn, Frederick S., et al.
Publicado: (2016)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
por: Resende, Uanderson, et al.
Publicado: (2019)

A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy
por: Varn, Frederick S., et al.
Publicado: (2018)

The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy
por: Xie, Zhen, et al.
Publicado: (2022)

Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
por: Zhao, Yanding, et al.
Publicado: (2020)

Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer Patients
por: Mazo, Claudia, et al.
Publicado: (2020)

Systematic analysis of hematopoietic gene expression profiles for prognostic prediction in acute myeloid leukemia
por: Varn, Frederick S., et al.
Publicado: (2015)

TP53 Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease
por: Takahashi, Shin, et al.
Publicado: (2023)

The association between breast density and breast cancer pathological response to neoadjuvant chemotherapy
por: Cullinane, C., et al.
Publicado: (2022)

Epithelial-Mesenchymal Transition Markers in Breast Cancer and Pathological Responseafter Neoadjuvant Chemotherapy
por: Elzamly, Shaimaa, et al.
Publicado: (2018)

Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy
por: Ai, Xiang, et al.
Publicado: (2020)

Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy
por: Varn, Frederick S., et al.
Publicado: (2018)

A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma
por: Kunnuru, Supreeth Kumar Reddy, et al.
Publicado: (2020)

Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Xu, Yuhao, et al.
Publicado: (2022)

Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer
por: Hsu, Ping-Ching, et al.
Publicado: (2020)

An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
por: Fu, Changfang, et al.
Publicado: (2021)

Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response
por: Xing, Ai-Yan, et al.
Publicado: (2021)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
por: Buzatto, I.P.C., et al.
Publicado: (2017)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Umutlu, Lale, et al.
Publicado: (2022)

Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy
por: Weiss, Anna, et al.
Publicado: (2018)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Clinical and Pathological Response to Neoadjuvant Anthracycline Based Chemotherapy in women with breast cancer
por: Olfa, Gharbi, et al.
Publicado: (2010)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
por: Hamy, Anne-Sophie, et al.
Publicado: (2019)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

E2F4 regulatory program predicts patient survival prognosis in breast cancer
por: Khaleel, Sari S, et al.
Publicado: (2014)

LncRNA Profile Study Reveals a Three-LncRNA Signature Associated With the Pathological Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer
por: Zeng, Ying, et al.
Publicado: (2019)

Stage IV Breast Implant–associated Anaplastic Large-cell Lymphoma with Complete Pathologic Response to Neoadjuvant Chemotherapy
por: Thibodeau, Renee, et al.
Publicado: (2019)

Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
por: Katayama, Maria Lucia Hirata, et al.
Publicado: (2019)

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Gwark, Sungchan, et al.
Publicado: (2021)

Exosomal Metabolic Signatures Are Associated with Differential Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
por: Joshi, Shriya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aencu7l5365n5o8tccmm8kkf60